Revlon restructures
This article was originally published in The Rose Sheet
Executive Summary
Color cosmetics leader announces worldwide restructuring plan that will allow it to reduce annualized costs by roughly $30 mil., according to May 28 release. Rightsizing strategy includes planned elimination of roughly 400 positions - 325 current employees and 75 open slots. "This action, which we are implementing immediately, will enable us to become a stronger, more financially sound organization while staying true to our vision of providing glamour, excitement and innovation to consumers through high-quality products at affordable prices," President and CEO Alan T. Ennis says. Restructuring and related charges are expected to total $20 mil., $17 mil. of which will be recognized in the firm's fiscal 2009 second quarter. Excluding those charges, Revlon anticipates "significant negative impact on net sales and profitability in [its] second-quarter 2009 results" due to slowing category growth, inventory declines, and unfavorable foreign currency, among other factors
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.